Plain-English translation of NCT06103838 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging scan called 18F-fluciclovine PET/CT to see if it can detect multiple myeloma better than the standard scan currently used. Researchers want to compare how well this new scan works compared to the scan doctors typically use right now. If this medication proves helpful, it could help doctors find myeloma earlier and track how well treatment is working.
Currently, doctors use standard imaging scans to find and measure multiple myeloma, but these scans sometimes miss disease or don't show the full picture. This trial exists to see if this new treatment approach can catch myeloma lesions more reliably, which could help doctors start treatment at the right time and choose the best therapy for each patient.
You likely qualify if…
You likely don't qualify if…
You will receive the new imaging scan at three different time points: at the start, after your initial treatment ends (or at 6 months if your myeloma has relapsed), and again if your disease progresses or at 5 years, whichever comes first. Each scan involves a small injection of radioactive tracer followed by imaging in a PET/CT machine. The study also compares your results to a standard scan you may already be getting as part of your regular care.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States